Fig. 1.

Schematic representation of experimental design. Dose dependent (2.5, 5, 10 mg/kg bw) intratracheal instillation of E171 TiO₂ were administered once in a day for more than 13 weeks called as treatment periods. From 14 to 17 weeks was recovery period and blood collection were done 17th week from 5 mg/kg bw for scRNAseq analysis. 10x chromium analysis, library preparation, and sequencing were performed at the single cell level for phenotypic identification and transcriptome observation, as indicated in the figure. Additionally, data visualization and processing were performed to assess immunological response of heterogeneous immune cell types